Cai Ruijuan, Lin Hongsheng, Cheng Qianwen, Mao Qiyuan, Zhang Chuchu, Tan Ying
Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Beijing Zhenren Hospital, Beijing, China.
Discov Oncol. 2024 Nov 17;15(1):668. doi: 10.1007/s12672-024-01526-8.
Lung adenocarcinoma (LUAD) is one of the most common malignant tumors. Although several treatments have been proposed, the long-term prognosis of this cancer is poor. Lipid droplets and mitochondria are important organelles that regulate energy metabolism in cells and are postulated to promote the occurrence and progression of tumors. However, few risk prediction models have been constructed based on lipid drop-mitochondria-related genes (LMRGs).
In this study, we constructed a lipid drop-mitochondrial (LD-M) risk score model based on data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Biological functions and clinical benefits associated with the various risk scores were analyzed using R software, GraphPad Prism 9, and the online database system.
An LD-M risk score model comprising ABLIM3, AK4, CAV2, CPS1, CYP24A1, DLGAP5, FGR, and SH3BP5, was developed and its predictive power was validated. The risk score was closely associated with the cell cycle. Immunophenoscore (IPS) and Tumor immune dysfunction and exclusion (TIDE) results demonstrated that the low-risk group was more sensitive to immunotherapy. Drug sensitivity analysis indicated that BMS-754807, ZM447439, SB216763, and other drugs had lower IC50 values in the low-risk group.
Our results suggest that the LD-M risk score is an effective prognostic indicator for individualized treatment of LUAD.
肺腺癌（LUAD）是最常见的恶性肿瘤之一。尽管已经提出了几种治疗方法，但这种癌症的长期预后很差。脂滴和线粒体是调节细胞能量代谢的重要细胞器，据推测它们会促进肿瘤的发生和发展。然而，基于脂滴 - 线粒体相关基因（LMRGs）构建的风险预测模型却很少。
在本研究中，我们基于来自癌症基因组图谱（TCGA）和基因表达综合数据库（GEO）的数据构建了一个脂滴 - 线粒体（LD - M）风险评分模型。使用R软件、GraphPad Prism 9和在线数据库系统分析了与各种风险评分相关的生物学功能和临床益处。
开发了一个由ABLIM3、AK4、CAV2、CPS1、CYP24A1、DLGAP5、FGR和SH3BP5组成的LD - M风险评分模型，并验证了其预测能力。风险评分与细胞周期密切相关。免疫表型评分（IPS）和肿瘤免疫功能障碍与排除（TIDE）结果表明，低风险组对免疫治疗更敏感。药物敏感性分析表明，BMS - 754807、ZM447439、SB216763等药物在低风险组中的IC50值较低。
我们的结果表明，LD - M风险评分是LUAD个体化治疗的有效预后指标。
